Prognostic significance of serum cystatin C in multiple myeloma

International Journal of Hematology

Volumn 95, Issue 5, 2012, Pages 545-550

  Nückel, Holger ^a   Langer, Christian ^b   Herget Rosenthal, Stefan ^c   Wichert, Marc ^d   Assert, Roland ^d   Dühner, Hartmut ^b   Dührsen, Ulrich ^a   Liebisch, Peter ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c Rotes Kreuz Krankenhaus Bremen   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Multiple myeloma; Prognostic marker; Serum cystatin C

Indexed keywords

BETA 2 MICROGLOBULIN; CREATININE; CYSTATIN C; MELPHALAN;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CREATININE BLOOD LEVEL; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; GENETIC DISORDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

ANTINEOPLASTIC AGENTS, ALKYLATING; CYSTATIN C; FEMALE; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; STEM CELL TRANSPLANTATION;

EID: 84862904212     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1049-2     Document Type: Article

References (27)

1. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol. 2000;65(3):175-81.
2. Kellum JA, Levin N, Bouman C, Lameire N. Developing a consensus classification system for acute renal failure. Curr Opin Crit Care. 2002;8(6):509-14. (Pubitemid 35388204)
3. Bellomo R, Kellum JA, Ronco C. Defining acute renal failure: physiological principles. Intensive Care Med. 2004;30(1):33-7. (Pubitemid 38147105)
4. Star R, Hostetter T, Hortin GL. New markers for kidney disease. Clin Chem. 2002;48(9):1375-6. (Pubitemid 34925769)
5. Murray PT, Le G Jr, Dos Reis MD, Pinsky MR, Tetta C. Physiologic endpoints (efficacy) for acute renal failure studies. Curr Opin Crit Care. 2002;8(6):519-25. (Pubitemid 35388206)
6. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, et al. Serum cystatin C: a replacement for creatinine as a biochemical marker of GFR. Kidney Int Suppl. 1994;47:S20-1.
7. Herget-Rosenthal S, Trabold S, Pietruck F, Holtmann M, Philipp T, Kribben A. Cystatin C efficacy as screening test for reduced glomerular filtration rate. Am J Nephrol. 2000;20(2):97-102. (Pubitemid 30224018)
8. Herget-Rosenthal S, Marggraf G, Husing J, Goring F, Pietruck F, Janssen O, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int. 2004;66(3):1115-22. (Pubitemid 39121017)
9. Abrahamson M, Olafsson I, Palsdottir A, Ulvsback M, Lundwall A, Jensson O, et al. Structure and expression of the human cystatin C gene. Biochem J. 1990;268(2):287-94. (Pubitemid 20193964)
10. Tenstad O, Roald AB, Grubb A, Aukland K. Renal handling of radiolabelled human cystatin C in the rat. Scand J Clin Lab Invest. 1996;56(5):409-14. (Pubitemid 26266006)
11. Coll E, Botey A, Alvarez L, Poch E, Quinto L, Saurina A, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000;36(1):29-34. (Pubitemid 30432560)
12. Mussap M, Dalla VM, Fioretto P, Saller A, Varagnolo M, Nosadini R, et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int. 2002;61(4):1453-61. (Pubitemid 34304506)
13. De VJ, Thykjaer T, Tarte K, Ensslen M, Raynaud P, Requirand G, et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene. 2002;21(44):6848-57. (Pubitemid 35221928)
14. Terpos E, Katodritou E, Tsiftsakis E, Kastritis E, Christoulas D, Pouli A, et al. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. Haematologica. 2009;94(3):372-9.
15. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3-9.
16. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-73. (Pubitemid 44264086)
17. Finney H, Newman DJ, Gruber W, Merle P, Price CP. Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clin Chem. 1997;43(6 Pt 1):1016-22. (Pubitemid 27246994)
18. Newman DJ, Cystatin C. Ann Clin Biochem. 2002;39(Pt 2): 89-104.
19. Strojan P, Oblak I, Svetic B, Smid L, Kos J. Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis. Br J Cancer. 2004;90(10):1961-8. (Pubitemid 38746337)
20. Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ, Brünner N. Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin Cancer Res. 2000;6(2):505-11. (Pubitemid 30111471)
21. Mulaomerović A, Halilbasić A, Cickusić E, Zavasnik-Bergant T, Begić L, Kos J. Cystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma. Cancer Lett. 2007;248(2):192-7. (Pubitemid 46330552)
22. Stabuc B, Vrhovec L, Stabuc-Silih M, Cizej TE. Improved prediction of decreased creatinine clearance by serum cystatin C: use in cancer patients before and during chemotherapy. Clin Chem. 2000;46(2):193-7. (Pubitemid 30104242)
23. Al-Tonbary YA, Hammad AM, Zaghloul HM, El-Sayed HE, Abu-Hashem E. Pretreatment cystatin C in children with malignancy: can it predict chemotherapy-induced glomerular filtration rate reduction during the induction phase? J Pediatr Hematol Oncol. 2004;26(6):336-41. (Pubitemid 38747722)
24. Mojiminiyi OA, Marouf R, Abdella N, Kortom M, Abdul-Razzak R. Serum concentration of cystatin C is not affected by cellular proliferation in patients with proliferative haematological disorders. Ann Clin Biochem. 2002;39(Pt 3):308-10. (Pubitemid 34494221)
25. Demirtaş S, Akan O, Can M, Elmali E, Akan H. Cystatin C can be affected by nonrenal factors: a preliminary study on leukemia. Clin Biochem. 2006;39(2):115-8. (Pubitemid 43255498)
26. Séronie-Vivien S, Toullec S, Malard L, Thomas F, Durrand V, Chatelut E. Contribution of the MDRD equation and of cystatin C for renal function estimates in cancer patients. Med Oncol. 2006;23(1):63-73. (Pubitemid 43787119)
27. Groesbeck D, Köttgen A, Parekh R, Selvin E, Schwartz GJ, Coresh J, Furth S. Age, gender, and race effects on cystatin C levels in US adolescents. CJASN. 2008;3(6):1777-85.